Je was op zoek naar: trifluridine (Engels - Kroatisch)

lonsurf trifluridine/tipiracil
lonsurf trifluridin/tipiracil

the active substances are trifluridine and tipiracil.
djelatne tvari su trifluridin i tipiracil.

trifluridine stops the growth of cancer cells.
trifluridin zaustavlja rast stanica raka.

it contains two active substances: trifluridine and tipiracil.
sadrži dvije djelatne tvari: trifluridin i tipiracil.

lonsurf 15 mg/6.14 mg tablets trifluridine/tipiracil
lonsurf 15 mg/6,14 mg tablete trifluridin/tipiracil

lonsurf contains two different active substances: trifluridine and tipiracil.
lonsurf sadrži dvije djelatne tvari: trifluridin i tipiracil.

tipiracil increases the level of trifluridine in the blood by slowing its breakdown.
tipiracil povećava razinu trifluridina u krvi usporavanjem njegove razgradnje.

serum albumin was found to significantly affect trifluridine clearance, with a negative correlation.
potvrđeno je da vrijednost serumskog albumin značajno utječe na klirens trifluridina, s negativnom korelacijom.

the absorbed trifluridine was metabolised, and excreted into urine as fty and trifluridine glucuronide isomers.
apsorbirani trifluridin se metabolizirao i izlučivao urinom kao fty i izomeri trifluridin glukuronida.

as a result, trifluridine interferes with dna function and prevents the cells from dividing and multiplying.
kao rezultat toga, trifluridin ometa funkciju dnk-a te sprečava diobu i množenje stanica.

as for the other exposure parameters of trifluridine and tipiracil hydrochloride, those appeared to be dose proportional.
kao i kod drugih parametara izloženosti trifluridinu i tipiracilkloridu i ovi su čini se proporcionalni dozi.

based on the mechanism of action, trifluridine is suspected to cause congenital malformations when administered during pregnancy.
na temelju mehanizma djelovanja, sumnja se da trifluridin može uzrokovati kongenitalne malformacije ako se primjeni tijekom trudnoće.

in the body, trifluridine is converted into an active form that is incorporated directly into dna, the genetic material of cells.
trifluridin se u tijelu pretvara u djelatni oblik koji se izravno ugrađuje u dnk, genetički materijal stanica.

in vitro evaluation indicated that trifluridine and fty had no inductive effect on human cyp1a2, cyp2b6 or cyp3a4/5.
in vitro ispitivanja upućuju da ni trifluridin, niti fty nemaju induktivno djelovanja na ljudske cyp1a2, cyp2b6 i cyp3a4/5.

based on the population pk analysis, there is no clinically relevant effect of age, gender or race on the pk of trifluridine or tipiracil hydrochloride.
temeljem analize populacijske pk, ne postoji klinički bitan utjecaj dobi, spola ili rase na pk trifluridina niti tipiracilklorida.

estimated (crcl) was a significant covariate for cl/f in both final models of trifluridine and tipiracil hydrochloride.
procjena klirensa (crcl) je bila značajna kovarijanta za cl/f u oba finalna modela trifluridina i tipiracilklorida.

the conversion of trifluridine into its active form occurs more readily in cancer cells than in normal cells, leading to higher levels of the active form of the medicine and a longer duration of action in cancer cells.
pretvaranje trifluridina u njegov djelatni oblik brže nastupa u stanicama raka nego u normalnim stanicama, što rezultira većim razinama djelatnog oblika lijeka i duljim djelovanjem u stanicama raka.

after single oral administration of lonsurf with [14c]-trifluridine, the total cumulative excretion of radioactivity was 60% of the administered dose.
nakon peroralne primjene jedne doze lonsurfa s [14c]-trifluridinom, ukupno kumulativno izlučivanje radioaktivnosti je iznosilo 60% primjenjene doze.

however, trifluridine is rapidly degraded by tpase and readily metabolised by a first-pass effect following oral administration, hence the inclusion of the tpase inhibitor, tipiracil hydrochloride.
međutim, trifluridin se brzo degradira tpazom i odmah metabolizira prvim prolaskom kroz jetru nakon oralne primjene, te je stoga u kombinaciji sa inhibitorom tpaze, tipiracilkloridom.

however, there was no accumulation for tipiracil hydrochloride, and no further accumulation of trifluridine with successive cycles (day 12 of cycles 2 and 3) of administration of lonsurf.
međutim, nije došlo do akumulacije tipiracilklorida niti daljnje akumulacije trifluridina sa sljedećim ciklusima (12. dan ciklusa 2. i 3.) primjene lonsurfa.